{"id":"fb312b4a-2cfe-4640-b6cb-2792cfcfb3db","modelId":"b1b7a2ef-267c-4571-a478-e999c75a5560","versionId":null,"locationId":"c2007b4e-a0f8-47d9-9254-ebbf1702a53e","operatorId":null,"ownerId":null,"slug":"synchron-upmc-pittsburgh","status":"operational","firstSeen":"2022-10-27T00:00:00.000Z","statusChangeReason":null,"contractType":null,"pilotOutcome":null,"endedAt":null,"unitsOnSite":null,"tasksPerformed":null,"shiftStructure":null,"hoursPerDay":null,"siteType":null,"operatorConfirmed":null,"humanSupervisionOnsite":null,"locationPrecisionTier":null,"deploymentScale":null,"siteEnvironment":null,"operatorType":null,"sourceQualityTier":null,"manufacturerSerial":null,"reviewStatus":"reviewed","sources":[{"url":"https://www.upmcphysicianresources.com/news/101524-command","name":"UPMC Physician Resources","title":"UPMC Served as Trial Site for COMMAND Trial"}],"notes":"UPMC was an approved COMMAND trial site. Dr. Raul Nogueira implanted device into two participants. COMMAND trial enrolled 6 patients total across all sites.","keyFacts":[],"reviewNote":null,"exposureHours":null,"deploymentMilesEstimate":null,"exposureBasis":null,"customerSegment":null,"scaleTier":null,"contractValueUsd":null,"contractValueBasis":null,"customerCompanyId":null,"customerExternalName":null,"createdAt":"2026-08-14T13:44:05.543Z","updatedAt":"2026-08-14T13:44:06.013Z","model":{"id":"b1b7a2ef-267c-4571-a478-e999c75a5560","companyId":"ac5afad9-cfd5-4b66-aa18-4d3aacf16560","modelName":"Synchron Stentrode","slug":"synchron-stentrode","description":"The Synchron Stentrode is an endovascular brain-computer interface implant that does not require open-brain surgery. Implanted via the jugular vein, it detects brain signals to enable patients with severe paralysis (ALS) to communicate via thought. The Stentrode has been tested in COMMAND (US) and SWITCH (Australia) clinical trials with no serious device-related adverse events.","formFactor":"wearable","industryVertical":null,"environment":null,"maturityStage":"pilot","lifecycleState":"active","supersededByModelId":null,"specs":{},"manufacturerSerial":null,"reviewStatus":"reviewed","sources":[{"url":"https://evtoday.com/news/synchrons-brain-computer-interface-evaluated-in-command-early-feasibility-study","title":"Synchron's BCI Evaluated in COMMAND Study","sourceName":"EV Today"}],"aliases":[],"collisionRisk":"low","reviewNote":null,"manufacturerTermForTeleop":null,"keyFacts":[{"label":"CEO","value":"Tom Oxley (Founder, neurologist, Mount Sinai)"},{"label":"Total funding","value":"over $345M ($200M Series D 2024, $75M Series C 2022)"},{"label":"Product","value":"Stentrode (endovascular BCI implant, no open-brain surgery)"},{"label":"Clinical trials","value":"COMMAND (US, FDA-approved), SWITCH (Australia, 4 patients)"},{"label":"Safety","value":"No serious device-related adverse events in 6 patients"},{"label":"Target","value":"Patients with severe paralysis (ALS) to communicate via thought"}],"createdAt":"2026-07-06T06:57:53.960Z","updatedAt":"2026-07-08T20:02:15.945Z","unitsInFieldClaimed":null,"unitsInFieldVerified":null,"unitsManufacturedClaimed":null,"unitsManufacturedVerified":null,"unitsAsOf":null,"unitsSource":null,"salesModel":null,"priceUndisclosedSince":null,"autonomyClass":null,"autonomyStatement":null,"autonomyStatementSource":null,"demoForensics":null,"exportControlClass":null,"minCommitment":null,"warrantyTerms":null,"serviceModel":null,"productionRateClaimed":null,"productionRateEvidenced":null,"teleopRatioDisclosed":null,"interventionRateDisclosed":null,"company":{"id":"ac5afad9-cfd5-4b66-aa18-4d3aacf16560","name":"Synchron","slug":"synchron","description":"Synchron is a brain-computer interface (BCI) company developing the Stentrode, a stentrode-based BCI implant that does not require open-brain surgery. Founded by neurologist Tom Oxley, the company has raised over $345M in total funding including a $200M Series D in 2024. Synchron's COMMAND and SWITCH clinical trials demonstrated no serious device-related adverse events across 6 patients, and the FDA has approved the Stentrode for early feasibility studies. The company is based in New York with origins in Melbourne, Australia.","status":null,"founded":2016,"hq":"New York, NY, USA","hqLat":40.7127281,"hqLng":-74.0060152,"hqGeocodedAt":"2026-08-05T14:50:15.330Z","hqAddress":null,"hqPrecision":null,"website":"synchrony.com","fundingTotal":"200000000","type":"hardware","reviewStatus":"reviewed","lifecycleState":"active","supersededByCompanyId":null,"sources":[{"url":"https://www.facebook.com/synchroninc/videos/-big-news-fda-approval-granted-for-synchrons-intent-trial-the-intent-trial-will-/2984514821739037/","title":"FDA approval granted for Synchron INTENT trial","sourceName":"Synchron"}],"keyFacts":[{"label":"CEO","value":"Tom Oxley (Founder, neurologist, Mount Sinai)"},{"label":"Total funding","value":"over $345M ($200M Series D 2024, $75M Series C 2022)"},{"label":"Product","value":"Stentrode (endovascular BCI implant, no open-brain surgery)"},{"label":"Clinical trials","value":"COMMAND (US, FDA-approved), SWITCH (Australia, 4 patients)"},{"label":"Safety","value":"No serious device-related adverse events in 6 patients"},{"label":"Target","value":"Patients with severe paralysis (ALS) to communicate via thought"}],"aliases":[],"collisionRisk":"low","reviewNote":null,"atsProvider":null,"atsSlug":null,"factoryLocations":null,"manufacturingCapacity":null,"orgType":null,"burnSignal":null,"litigationEvents":null,"insurancePostureDisclosed":null,"unitEconomicsDisclosed":null,"tickerSymbol":null,"stockExchange":null,"secCik":null,"revenueUsd":null,"revenueBasis":null,"revenueAsOf":null,"employeeCount":null,"employeeCountBasis":null,"employeeCountAsOf":null,"marketCapUsd":null,"marketCapAsOf":null,"marketCapSource":null,"createdAt":"2026-07-06T06:54:46.200Z","updatedAt":"2026-08-05T14:52:40.652Z"}},"version":null,"location":{"id":"c2007b4e-a0f8-47d9-9254-ebbf1702a53e","name":"Pittsburgh, Pennsylvania, USA","slug":"pittsburgh-pennsylvania-usa","kind":"hospital","parentLocationId":null,"region":null,"lat":null,"lng":null,"reviewStatus":"reviewed","aliases":[],"collisionRisk":"high","reviewNote":null,"createdAt":"2026-08-14T13:44:05.155Z","updatedAt":"2026-08-14T16:09:25.839Z"},"operator":null,"owner":null,"derived":{"trustTier":"unverified","currentPosture":null},"jsonLd":{"@context":"https://schema.org","@type":"Event","@id":"https://registry.deploy.report/deployments/synchron-upmc-pittsburgh","url":"https://registry.deploy.report/deployments/synchron-upmc-pittsburgh","name":"Synchron Stentrode at Pittsburgh, Pennsylvania, USA","identifier":"fb312b4a-2cfe-4640-b6cb-2792cfcfb3db","startDate":"2022-10-27T00:00:00.000Z","location":{"@type":"Place","@id":"https://registry.deploy.report/locations/pittsburgh-pennsylvania-usa","name":"Pittsburgh, Pennsylvania, USA"},"organizer":{"@type":"Organization","@id":"https://registry.deploy.report/companies/synchron","name":"Synchron"},"about":{"@type":"Product","@id":"https://registry.deploy.report/models/synchron-stentrode","name":"Synchron Stentrode"},"publisher":{"@id":"https://deploy.report/#organization"}},"framework_metadata":{"framework_schema_version":"0.1.0","verification_status":"verified","maturity_stage":"pilot","lifecycle_state":"active","architectural_position":{"cohort":"wearable","sub_cohorts":[]},"within_cohort_verified_vs_claimed_pair":null,"cap_flags":[],"verification_depth":{"sources_count":1,"primary_source_types":[]}}}